Abivax reports excellent efficacy and safety of ABX464 in phase 2b clinical trial in ulcerative coli
Search jobs 24-May-2021 Abivax reports excellent efficacy and safety of ABX464 in phase 2b clinical trial in ulcerative colitis and plans to proceed to phase 3 DGAP-News: ABIVAX / Key word(s): Study results 24.05.2021 / 18:30 The issuer is solely responsible for the content of this announcement. Abivax reports excellent efficacy and safety of ABX464 in phase 2b clinical trial in ulcerative colitis and plans to proceed to phase 3 Primary endpoint ...
Source: pharmiweb.com